The Disease Cancelling Technology aspect of our platform is based on the notion that engineering medicines to reverse a disease signal across multiple relevant genes will yield drug candidates with a higher likelihood of success compared to traditional drug discovery methods.
The biology side of our platform (Cosiner) enables hypothesis-free, data-driven target identification. This platform uses gene expression from highly curated human patient datasets, not targets identified in the literature. Cosiner not only produces new targets and more sophisticated ways to drug existing targets, but also specific in vivo/in vitro testable genes, relevant concentrations and timepoint information driving the result.
Fluency screens small molecule compound libraries for hits against identified targets generating binding affinity rankings at near experimental level precision. This platform provides mechanistic insights into regions of the protein being bound and can rank the binding for 20 million compounds to a protein in just a day.
These platforms are not limited to a single aspect or pathology, rather they are disease-agnostic, which enables them to help engineer drug candidates for countless disorders. Immuneering’s platform has the potential to deliver more value to the healthcare system than traditional drug discovery and development.